TEVA ▾TradingViewOVTLYR consoleNews (1w)Earnings search — Teva Pharmaceutical Industries Limited

Healthcare · ETF XLV · as of 2026-09-21

Daily · EMA 10 / 20 / 50 · SMA 200 · VolPress: buy/sell split, 20-SMA, white dot = above avg · · E = earnings · RS vs SPY ⓘ · ● RS new high ⓘ
TEVA
Teva Pharmaceutical Industries Limited NYQ
Healthcare · Drug Manufacturers - Specialty & Generic

Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Market cap
37.5B
P/E (TTM)
29.9
EPS (TTM)
1.34
Employees
32,842
IPO
1982-02-16
Website
tevapharm.com

Price & today

$40.06 ATR(14) 1.23 (3.06%)
Stock today+2.77%
Sector ETF today+0.37%
Residual (stock-specific)+2.40%

Sector correlation

20-day correlation with XLV0.41
60-day correlation with XLV0.30
Status normal

Decoupling fires when 60d corr − 20d corr > 0.20: stock used to track its sector but the relationship has weakened recently.

Technicals

10 EMA$38.50
20 EMA$37.73
50 EMA$36.26
EMA stackBULLISH
RSI(14)66.8
52-week high distance+7.26%
52-week low distance+167.24%

Signals

Market F&G45.6
Bull%12.2%
OVTLYR status BUY (2d)
Sector rank#386
Next earnings 2026-11-04 (TNS, 44d)
TradingView OVTLYR console More news (Google) Sector dashboard (XLV)

MarketSmith metrics - our compute

RS Rating
93.3
ADR%
3.2
RMV (tight)
71.0
Ext (ATR>20EMA)
1.9
Rel Vol
113.0%
U/D 50d
1.43
U/D 25d
1.25
Accum/Dist 25d
6 / 3
EPS YoY
-97.0%
LoD dist
138.0
Off 52w High
1.8%
Above 52w Low
120.0%
1W / 1M
+3.5 / +8.8
Avg $Vol 50d
187.8M
Mkt Cap (B)
46.6
Trend 8/8
YES
Leads Group
YES
Sector XLV
+0.8% 1W
Base len (VCP)
21wk (7/8)
Coil (base shape)
85TVPX
What do these abbreviations mean?
RS Rating
- IBD-style relative strength vs SPY (weighted 3/6/9/12-mo). 70+ = leaders pool, 80+ = strong.
ADR%
- average daily range over 20 days. 4%+ = the fast movers the playbook prefers (selection order, not a gate).
RMV (tight)
- Relative Measured Volatility, 15 bars, scaled 0-100. <15 = tight coiled base (green), <35 moderate, high = loose/expanding - not a base right now.
Ext (ATR>20EMA)
- how many ATRs price sits above its 20-EMA. ≤1 = in value (green), >2 = extended/chasing (red) - prefer a pullback.
Rel Vol
- latest volume vs the 50-day average. 100% = normal; 140%+ = breakout confirmation.
U/D 50d / 25d
- up-day vs down-day volume over the window. 1.1+ = net accumulation (institutions buying); under 0.9 on the 25d = net selling.
Accum/Dist 25d
- heavy-volume up days vs heavy-volume down days in the last 25 sessions (close moved 0.2%+ on above-average volume). The institutional-participation footprint; 5+ distribution days = O'Neil caution line.
LoD dist
- close distance above the day low in % of ATR (100 = one full ATR off the low). High = strong close.
Off/Above 52w
- trend-template legs: within 25% of the 52-week high, at least 25% above the 52-week low.
Trend 8/8
- all 8 Minervini Trend Template criteria pass. Discovery floor, NOT an entry signal - entries come from the VCP pivot.
Base len (VCP)
- weeks since the VCP base started on the latest scan. 10wk+ bases carry the edge; short stacked bases test below random.

Fundamentals & valuation - reference, not entry inputs

P/E (TTM)
29.9
Fwd P/E
12.9
PEG
1.4
Price/Book
5.0
Profit margin
9.0%
ROE
21.6%
Debt/Equity
205.6
Rev growth
+2.3%
Analyst target
$40 (+0%)
Analyst rating
STRONG_BUY
Institutional %
60.4%
Insider %
0.0%
Float %
93.0%
Valuation and analyst figures are Yahoo company stats (weekly refresh, ~3,000 larger names - blanks are honest gaps); logo, employees, website and IPO date are Massive company reference. Momentum/VCP entries do not use valuation - this card is context so you do not have to leave the page.

Company data - context read, not entry inputs

Industry rank
43 / 146
Industry
Drug Manufacturers - Specialty & Generic
Float
1.08B
Float turnover 20d
0.5%
Avg $Vol 20d / 50d
185.4M / 187.8M
Days to cover
5.2
Short % float
2.6%
Institutional %
60.4%
Weinstein stage
2
Float, short interest and institutional % come from Yahoo company stats, refreshed weekly for ~3,000 larger names - a blank means Yahoo does not publish the figure for this stock, not that it is zero. Dollar volume and float turnover are computed from our own price bars; industry rank from our rotation data; stage from the weekly chart.

Quarterly EPS - earnings acceleration

A dash in %Chg is deliberate: the year-ago figure was a loss, so a growth % would be meaningless. A dash in Sales means we have no revenue figure for that quarter - read it as a gap in our data, not as zero revenue.

QuarterEPS ($)%Chg YoYSales ($M)%Chg
Nov-24 0.69 +15% 4,332.0 +13%
Jan-25 0.71 -29% 4,229.0 -5%
May-25 0.52 +8% 3,891.0 +2%
Jul-25 0.66 +8% 4,176.0 +0%
Nov-25 0.78 +13% 4,480.0 +3%
Jan-26 0.96 +35% 1,500.0‡ -
Apr-26 0.53 +2% 3,982.0‡ +2%
Jul-26 0.02 -97% 4,142.0 -1%
† = SEC carries this same fiscal quarter under a second period-end with a materially different figure (hover for it) - a restatement, merger recast or successor-period split; %Chg is blanked when the two are more than 15% apart. It fires only when the two period-ends DISAGREE, so it is a floor, not a guarantee that the rest of the column shares one basis · ‡ = the revenue concept changed from the previous quarter WITH A FIGURE (hover for both) - a blank row in between is skipped, as the eye does - a step at that row is a change of basis, not necessarily of business · EPS = Yahoo eps_actual (the figure MarketSmith/Deepvue show) - whether a given quarter is GAAP or excludes a one-off follows the filing, so it can sit either side of another vendor's number; AAPL's Oct-24 row, the Sep-2024 fiscal quarter, is $0.97 here - GAAP, including the EU tax charge - where TradingView's year implies $1.64 · Sales ($M) = SEC EDGAR quarterly revenue (fiscal Q4 derived as FY minus 9-mo) · quarter = report month · %Chg blank = prior-year base under $0.05 (not meaningful).

Recent news - our DB (Finnhub + OVTLYR)